Mylan Recalls Amlodipine and Benazepril Capsules Due to CGMP Deviations
Mylan Pharmaceuticals is recalling specific lots of Amlodipine Besylate and Benazepril HCl capsules because they were not manufactured according to Good Manufacturing Practices.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score (4) according to the rubric, as it involves a product that could cause temporary or medically reversible adverse health consequences.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling 4,722 bottles of Amlodipine Besylate and Benazepril HCl Capsules, 2.5 mg/10 mg, 100-count bottles. The affected products are identified by NDC 0378-6895-01 and lot numbers 2003156, 2003157, 2003155, and 3043491.
The recall was initiated because the pharmaceuticals were produced and distributed with active ingredients that were not manufactured according to Good Manufacturing Practices (CGMP Deviations). The FDA has classified this recall as Class II.
The affected products were distributed nationwide and in Puerto Rico. Consumers and healthcare providers should check their inventory for these specific lot numbers and contact their pharmacist or Mylan Pharmaceuticals for further instructions on how to handle the recalled medication.
The recalled product
- Product
- Amlodipine Besylate and Benazepril HCl Capsules, 2.5 mg/10 mg, 100-count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A, NDC 0378-6895-01
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Affected units
- 4,722
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 2003156
- 2003157
- 2003155
- 3043491
Distribution
Part of a larger recall action
This product is one of 12 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- ModerateMylan Recalls Amlodipine and Benazapril Capsules Due to Cleaning Deviations
FDA (Drugs) · 2018-05-23
- SevereMylan Amlodipine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2016-08-31
- SevereMylan Amlodipine Besylate Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2016-08-31
- HighMylan Recalls Loxapine Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2018-05-30
- LowLupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-09-14
- SevereMylan Recalls Ciprofloxacin Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2015-01-28